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Background. Increasing evidence suggests that angiotensin-
(1–7) [Ang-(1–7)] acts as an endogenous antagonist of Ang II
when the renin-angiotensin system (RAS) is activated. In the
present study, we therefore compared the effects of acute in-
trarenal (i.r.) Ang-(1–7) receptor blockade on renal function
under conditions of normal and increased intrarenal Ang II
concentration.
Methods. Salt-replete Hannover-Sprague Dawley rats
(HanSD) served as control animals. As models with enhanced
action of Ang II we first used transgenic rats harboring the
Ren-2 renin gene (TGR), second, Ang II-infused rats, third, 2-
kidney, 1-clip (2K1C) hypertensive rats on normal salt intake,
and fourth, salt-depleted TGR and HanSD.
Results. I.r. Ang-(1–7) receptor blockade elicited significant
decreases in glomerular filtration rate (GFR), renal plasma flow
(RPF), and sodium excretion in 2K1C rats, and in salt-depleted
TGR and HanSD. In contrast, i.r. Ang-(1–7) receptor blockade
did not significantly change GFR, RPF, and sodium excretion
in salt-replete TGR and HanSD, or in Ang II-infused rats.
Conclusion. These findings suggest that under conditions of
normal intrarenal RAS activity and increased intrarenal Ang II
action by infusion of Ang II or by insertion of a renin gene in
salt-replete conditions, Ang-(1–7) is not an important factor in
the regulation of renal function. In contrast, under conditions of
endogenous RAS activation due to clipping of the renal artery
or to sodium restriction, Ang-(1–7) serves as opponent of the
vasoconstrictor actions of Ang II.
The critical role of the renin-angiotensin system (RAS)
in the regulation of renal function and extracellular fluid
volume has been recognized for many years [1]. The in-
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appropriate activation of this powerful system is a major
factor contributing to the pathophysiology of hyperten-
sion [2]. Angiotensin II (Ang II) has been championed for
many years as the only biologically active component of
the RAS. However, it is now clear that several angiotensin
peptides exert important vasoactive actions. From these,
angiotensin-(1–7) [(Ang-(1–7)], a heptapeptide derived
from angiotensin I (Ang I) and/or from Ang II, possesses
probably the most important effects, especially in the kid-
ney [3–8]. The hypothesis that Ang-(1–7) may act as an
endogenous antagonist to the actions of Ang II, espe-
cially in situations of an overactive RAS, was originally
provided by Ferrario et al [9–11], and confirmed by San-
tos et al [12]. However, the role of Ang-(1–7) as a natri-
uretic and vasodilatory peptide, which would represent a
physiologic endogenous mechanism that opposes the hy-
pertensinogenic actions of Ang II, remains controversial.
In agreement with this notion, we and others have
shown that Ang-(1–7) infusion produced a marked na-
triuresis in the kidney of normotensive rats and dogs
[5, 13, 14]. In addition, it has been reported that Ang-
(1–7) causes afferent arteriolar vasodilatation [7], and
even if devoid of any vasodilator actions by itself, it
at least antagonizes the renal vasoconstrictor effects of
Ang II [6]. Moreover, treatment with either an Ang-(1–
7) monoclonal antibody or with the selective Ang-(1–
7) receptor antagonist [7-D-Ala]-Ang-(1–7) [15] elicited
a dose-dependent rise in blood pressure (BP), and re-
versed to a significant degree the BP lowering effects of
angiotensin-converting enzyme (ACE) inhibitors or Ang
II subtype 1 (AT1) receptor antagonists in hypertensive
and salt-depleted rats [16, 17].
In contrast to the hypothesis that Ang-(1–7) serves as
natriuretic and vasodilatory agent that counteracts pres-
sor effects of Ang II, Ang-(1–7) was shown to exhibit
antidiuretic actions in water-loaded rats [18], and to stim-
ulate renal tubular sodium reabsorption in normotensive
rats [4, 18–20]. Besides this, it has been also reported
that Ang-(1–7) does not exert vasodilator and/or Ang II
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opposing actions in the renal circulation [21]. Although it
is difficult to reconcile such contradictory findings, based
on their comprehensive analysis of studies regarding
the physiologic and pathophysiologic role of Ang-(1–7),
Santos et al [12] have suggested that the overall activity of
the RAS, as it results from experimental manipulations,
markedly influences BP and renal functional responses
to Ang-(1–7).
Recent studies have demonstrated that in pregnant rats
and animals exposed to combined inhibition of both ACE
and neutral endopeptidase 24.11, renal concentrations of
Ang-(1–7) and urinary Ang-(1–7) excretion are markedly
augmented without altering Ang-(1–7) levels in the cir-
culation [22, 23]. In addition, we showed previously that
exogenous infusion of a relatively high dose of Ang-(1–
7) prevented the decrease in sodium excretion from in-
trarenal (i.r.) infusion of exogenous Ang II [14]. These
data would suggest that Ang-(1–7) could act as an in-
trarenal endogenous physiologic antagonist of Ang II un-
der conditions of elevated kidney Ang II levels. However,
in view of the aforementioned results from previous stud-
ies, the relevance of the actions of Ang-(1–7) as a mecha-
nism counteracting the effects of enhanced Ang II levels
on renal function remains unknown. Thus, the objective
of the present study was to compare the effects of acute
i.r. Ang-(1–7) receptor blockade on renal function under
conditions of “normal” and “enhanced” intrarenal Ang II
activity. As experimental models of Ang II-dependent
hypertension, first we used hypertensive heterozygous
male transgenic rats harboring the Ren-2 renin gene
(TGR) [24], second, Ang II-infused hypertensive rats,
and third, 2-kidney, 1-clip (2K1C) Goldblatt hypertensive
rats. Since restriction of dietary sodium chloride in-
take is closely associated with a rise in renal Ang II
content, normotensive transgene-negative Hannover-
Sprague Dawley rats (HanSD) and TGR exposed to salt
depletion were used as additional models of enhanced
intrarenal Ang II activity. HanSD fed a normal salt diet
(NS) served as controls with normal intrarenal Ang II
activity.
METHODS
The studies were performed in accordance with guide-
lines and practices established by the Institute for Clinical
and Experimental Medicine Animal Care and Use Com-
mittee, and are also in accordance with laws in the Czech
Republic and the Federal Republic of Germany.
Animals
All experimental models used in this study were de-
signed in a way that the acute renal functional studies
were performed in animals at the same age (i.e. in 52-day-
old rats). The rationale for using such animals is based on
previous studies which demonstrated that TGR at this age
are already hypertensive, but do not show hypertension-
induced structural changes in the peripheral and renal
vasculature. In addition, it has been reported that TGR
at this age exhibit exaggerated renal vascular responsive-
ness to Ang II, and enhanced sodium excretory responses
to Ang II type 1 (AT1) receptor blockade ([25, 26], and
for review see [27]).
Hypertensive heterozygous TGR
Male heterozygous TGR of the hypertensive line TGR
(mRen2)27 in their early phase of hypertension (52 days
old) were used as a well-defined monogenetic model
of Ang II-dependent hypertension [24]. Age-matched
HanSD rats served as transgene-negative normotensive
controls. All TGR and HanSD animals used in the present
study were bred at the Center for Experimental Medicine
of the Institute for Clinical and Experimental Medicine
from stock animals supplied from the Max Delbru¨ck Cen-
ter for Molecular Medicine, Berlin, Germany.
2K1C Goldblatt hypertensive rats
After weaning, male HanSD rats (28 days old) were
anesthetized with thiopental sodium (60 mg/kg i.p.). The
right renal artery of each animal was isolated through
a flank incision and, as described previously [28], a sil-
ver clip (0.25 mm internal gap) was placed on the renal
artery. The acute experiments were performed 25 days
after placement of the clip.
Ang II-infused hypertensive rats
Male HanSD rats (39 days old) were anesthetized
as described above, and osmotic minipumps (Model
2002, Alza Corp., CA, USA) containing Ang II (Sigma
Chemical Co., Prague, Czech Republic) were implanted
subcutaneously at the dorsum of the neck as described
previously [29, 30]. Ang II was infused at a rate of
80 ng/min. Previous studies have indicated that such a
dose of Ang II leads to a slowly developing hypertension
[29, 30]. The acute experiments were performed on day
13 after implantation of the minipumps.
Salt-depleted HanSD rats and TGR
Male HanSD rats (49 days old) and TGR were
given furosemid (F) for 1 day added to drinking water
(40 mg/L, Furon; Merckle Corp., Blaubeuren, Germany),
and thereafter were fed a low sodium (LS) diet for 3 days
(<0.01 g NaCl/100 g rat chow, C 1036; Altromin, Lage,
Germany). Previous studies have demonstrated that this
type of salt depletion leads to potent stimulation of the
RAS [16, 17, 31].
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Salt-replete HanSD rats
Male HanSD rats on NS intake (0.6 g NaCl/100 g rat
chow, C 1000; Altromin) served as controls with presum-
ably normal intrarenal Ang II activity.
Renal functional studies
On the day of the experiment, animals were anes-
thetized with thiopental sodium (60 mg/kg i.p.), and
placed on a thermoregulated table to maintain body
temperature at 37 to 37.5◦C. A tracheostomy was per-
formed to maintain a patent airway, and the exterior end
of the tracheal cannula was placed inside a small plas-
tic chamber, into which humidified 95% O2/5% CO2
mixture was continuously passed. This procedure im-
proves the stability of arterial pressure in anesthetized
rats [28]. The right jugular vein was catheterized with
PE-50 tubing for intravenous administration of solutions,
and additional thiopental sodium as needed to main-
tain an appropriate level of anesthesia, which was reg-
ularly tested with corneal reflex throughout the exper-
iment. The right femoral artery was cannulated to al-
low continuous monitoring of arterial BP and blood
sampling. Mean arterial pressure (MAP) was monitored
with a pressure transducer (model MLT 1050; ADInstru-
ments, Chalgrove, UK) and recorded on the computer
using a computerized data-acquisition system (Power-
Lab/4SP, ADInstruments). The left kidney was exposed
via a flank incision, isolated from the surrounding tis-
sue, and placed in a Lucite cup, and the ureter was can-
nulated with a PE-10 catheter. During surgery, an iso-
tonic saline solution containing bovine serum albumin
(6%) (Sigma Chemical Co.) was infused at a rate of
20 lL/min. After surgery, isotonic saline solution con-
taining p-aminohippurate sodium (PAH; Merck, Sharp &
Dohme, West Point, PA, USA) (1.5%), and polyfructosan
(Inutest; Laevosan, Linz/Donau, Austria) (7.5%) was in-
fused at the same infusion rate. In addition, a tapered PE-
10 catheter was inserted into the left renal artery via the
left femoral artery for selective i.r. administration of ei-
ther saline vehicle or [7-D-Ala]-Ang-(1–7). This catheter
was kept patent by a continuous infusion of heparinized
isotonic saline at a rate of 4 lL/min throughout the exper-
iment. In previous studies, it was demonstrated that this
procedure allows selective administration of drugs (e.g.,
bolus doses of Ang II and candesartan, an AT1 receptor
antagonist) without spillover into the systemic circula-
tion, and permits selective blockade of receptors in the
renal vasculature without altering MAP [28, 29]. After
completion of the above-mentioned surgical procedures,
an equilibration period of 50 minutes was allowed for
the animals to establish steady state before initiating 2
30-minute control urine collections. Coincident with the
urine collections, arterial blood samples were collected to
allow determination of control renal function. Thereafter,
i.r. infusion of isotonic saline with or without 7-D-Ala-
Ang-(1–7) (5 ng/min) was started and continued through-
out the experimental clearance periods. As demonstrated
in previous studies, this dose of 7-D-Ala-Ang-(1–7) is able
to block the renal functional and vasodilator action of
Ang-(1–7), and is specific for the proposed Ang-(1–7) re-
ceptor in all tissues ([4, 7, 15, 32], and for review see [12]).
Since it has been suggested that higher doses of 7-D-Ala-
Ang-(1–7) can potentially elicit nonspecific effects (for
review see [12]), we decided not to employ larger doses
of 7-D-Ala-Ang-(1–7).
7-D-Ala-Ang-(1–7) was purchased from Bachema
(Bubendorf, Switzerland).
Experimental groups consisted of: HanSD rats fed NS
diet + i.r. vehicle saline (N = 9); HanSD rats fed NS
diet + i.r. 7-D-Ala-Ang-(1–7) (N = 11); HanSD rats fed
LS diet and given F + i.r. vehicle saline (N = 8); HanSD
rats fed LS diet and given F + i.r. 7-D-Ala-Ang-(1–7)
(N = 14); TGR fed NS diet + i.r. vehicle saline (N =
9); TGR fed NS diet + i.r. 7-D-Ala-Ang-(1–7) (N = 14);
TGR fed LS diet and given F + i.r. vehicle saline (N = 8);
TGR fed LS diet and given F + i.r. 7-D-Ala-Ang-(1–7)
(N = 12); Ang II-infused rats + i.r. vehicle saline (N = 9);
Ang II-infused rats + i.r. 7-D-Ala-Ang-(1–7) (N = 13);
2K1C rats + i.r. saline vehicle (N = 8); 2K1C rats + i.r.
7-D-Ala-Ang-(1–7) (N = 10).
Urine volume was measured gravimetrically. Sodium
and potassium concentrations were determined by flame
photometry. Inulin and PAH concentrations were mea-
sured colorimetrically. Inulin clearance was used as an
index of GFR and PAH clearance as an index of RPF,
and values are given per gram of kidney weight.
Data are expressed as mean ± SEM. Statistical com-
parisons within groups were conducted by the use of anal-
ysis of variance (ANOVA) for repeated measurements,
followed by Newman-Keuls test. One-way ANOVA was
used for comparisons between groups. Values exceeding
the 95% probability limits (P < 0.05) were considered
statistically significant.
RESULTS
Basal values for MAP, renal hemodynamics, and
sodium excretion (average from 2 control clearance pe-
riods) are summarized in Table 1. To evaluate renal func-
tional responses to experimental manipulations, we used
percent changes from baseline values. Since experimen-
tal manipulations did not cause significantly different
responses between experimental periods 1 and 2 in all
groups, we decided for clarity of presentation to use only
the data from the experimental clearance period 2.
Effects of i.r. Ang-(1–7) receptor blockade on MAP,
GFR, and RPF
No significant changes in MAP were observed in any
of the experimental groups during i.r. infusion of either
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Table 1. Basal values of mean arterial pressure, renal hemodynamics, and urinary flow rate and sodium excretion (mean from 2 control clearance
periods) of individual experimental groups
MAP GFR RPF UNaV FENa V
Group N mm Hg mL/min/g mL/min/g lmol/min/g % lL/min/g
HanSD + NS diet 20 124 ± 2 1.39 ± 0.08 3.21 ± 0.15 0.63 ± 0.12 0.35 ± 0.08 10.3 ± 1.1
HanSD + LS diet + F 22 123 ± 3 1.36 ± 0.09 3.26 ± 0.18 0.10 ± 0.02a 0.09 ± 0.02a 9.1 ± 0.7
TGR + NS diet 23 159 ± 3a,b 1.49 ± 0.13 3.73 ± 0.29 0.71 ± 0.13 0.38 ± 0.08 11.5 ± 1.1
TGR + LS diet + F 20 137 ± 5a 1.46 ± 0.17 3.62 ± 0.24 0.06 ± 0.01a 0.03 ± 0.01a 8.3 ± 0.8
Ang II-infused rats 22 154 ± 2a,b 1.29 ± 0.14 3.16 ± 0.22 0.44 ± 0.09 0.25 ± 0.06 8.2 ± 0.7
2K1C rats 18 155 ± 3a,b 0.98 ± 0.09a 2.15 ± 0.18a 0.34 ± 0.09 0.27 ± 0.08 7.9 ± 1.1
Abbreviations are: TGR, renin-2 transgenic rats; HanSD, transgen-negative rats; 2K1C rats, 2-kidney, 1-clip Goldblatt hypertensive rats; MAP, mean arterial pressure;
GFR, glomerular filtration rate; RPF, renal plasma flow; UNaV, absolute sodium excretion; FENa, fractional sodium excretion; V, urine flow; NS, normal salt diet; LS,
low sodium diet; F, furosemide. Values are mean ± SEM. Renal hemodynamics, urine flow, and sodium excretion are given per gram of kidney weight.
aP < 0.05 compared with unmarked values.
bP < 0.05 compared with TGR fed the LS diet.
vehicle or the Ang-(1–7) antagonist, which therefore did
not spill over into the systemic circulation in amounts
sufficient to produce significant blockade of extrarenal
Ang-(1–7) receptors. As shown in Figure 1, i.r. Ang-(1–7)
receptor blockade did not influence either GFR or RPF
in HanSD rats (+1 ± 2 and +3 ± 2%) and in TGR fed
the NS diet (−4 ± 3 and +3 ± 3%), or in Ang II-infused
rats (−3 ± 2 and −6 ± 4%).
I.r. Ang-(1–7) receptor blockade resulted in significant
decreases in GFR and RPF in 2K1C rats (−16 ± 3 and
−18 ± 3%, P < 0.05 vs. control periods) and in sodium-
depleted HanSD rats (−28 ± 4 and −27 ± 4%, P < 0.05
vs. control periods) and TGR (−19 ± 3 and −17 ± 4%,
P < 0.05 vs. control periods) fed the LS diet and given
F. Time-control rats (given saline vehicle only) did not
reveal significant changes in GFR and RPF in any exper-
imental group; therefore, data are not shown.
Effects of i.r. Ang-(1–7) receptor blockade on renal
sodium excretion and urine flow rate
As shown in Figure 2, i.r. Ang-(1–7) receptor blockade
did not change absolute and fractional sodium excretion
in HanSD rats fed the NS diet (−5 ± 4 and −3 ± 3%),
in Ang II-infused rats (+3 ± 3 and +4 ± 3%), and in
TGR fed the NS diet (+4 ± 3 and +6 ± 4%). I.r. Ang-(1–
7) receptor blockade decreased absolute and fractional
sodium excretion in 2K1C rats (−34 ± 4 and −35 ± 4%,
P < 0.05 vs. control periods) and in HanSD rats (−22 ±
5 and −20 ± 4%, P < 0.05 vs. control periods) and TGR
fed the LS diet and given F (−24 ± 4 and −27 ± 4%, P <
0.05 vs. control periods).
Likewise, i.r. Ang-(1–7) receptor blockade did not
cause significant changes in urine flow in HanSD rats fed
the NS diet (+2 ± 2%), in Ang II-infused rats (+4 ± 3%),
and in TGR fed the NS diet (+3 ± 3%). I.r. Ang-(1–7)
receptor blockade elicited significant decreases in urine
flow in 2K1C rats (−10 ± 2%, P < 0.05 vs. control peri-
ods), and in HanSD rats (−13 ± 3%, P < 0.05 vs. control
periods) and TGR fed LS and given F (−9 ± 2%, P < 0.05
vs. control periods). Time-control animals again did not
show significant changes in sodium excretion or in urine
flow. No significant changes in potassium excretion were
found in any of the groups (data are not shown).
DISCUSSION
To our knowledge, this is the first comprehensive study
elucidating the relevance of intrarenal Ang-(1–7) in the
regulation of renal hemodynamics and sodium excretory
function in various models with normal or enhanced in-
trarenal action of Ang II. We found that the selective i.r.
Ang-(1–7) receptor blockade did not elicit alterations in
renal function in HanSD rats and TGR fed the NS diet or
in Ang II-infused hypertensive rats. In contrast, i.r. Ang-
(1–7) receptor blockade caused significant decreases in
renal hemodynamics and proportional decreases in both
absolute and fractional sodium excretion in salt-depleted
HanSD rats and TGR and in 2K1C Goldblatt hyperten-
sive rats. These data suggest that under conditions of nor-
mal sodium intake in rats with increased intrarenal action
of Ang II, either by infusion of Ang II or by insertion of
a renin gene, Ang-(1–7) does not play an important role
in the regulation of renal function. In contrast, our find-
ings indicate that under conditions of sodium depletion
in normotensive HanSD rats and hypertensive TGR, or
in hypertensive rats due to clipping of the contralateral
renal artery, Ang-(1–7) serves as an important endoge-
nous opponent of Ang II that counteracts, at least in part,
the vasoconstrictor actions of an enhanced action of in-
trarenal Ang II. Ang-(1–7) may thus contribute to main-
tain renal hemodynamics and excretory function within
physiologic levels in these models of hypertension, and
may thereby exert a renoprotective role. However, the
underlying mechanism(s) responsible for the renopro-
tective effect of Ang-(1–7) remains unknown. On one
hand, it might be that Ang-(1–7) antagonizes the vaso-
constrictor effect of Ang II by competitive binding at
the Ang II type 1 (AT1) receptor, as suggested by some
investigators [5, 33–35]. On the other hand, it has been
shown that Ang-(1–7) potentiates the vasodilator actions
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Fig. 1. Percent changes in glomerular filtra-
tion rate (A) and renal plasma flow (B) in
response to intrarenal Ang-(1–7) receptor
blockade. HanSD + NS, transgene-negative
normotensive rats fed normal sodium diet;
Ang II, angiotensin II-infused hypertensive
rats; 2K1C, 2-kidney, 1-clip Goldblatt hyper-
tensive rats; TGR + NS, renin-2 transgenic
hypertensive rats fed normal sodium diet;
HanSD + LS + F, transgene-negative nor-
motensive rats fed low sodium diet and given
furosemide; TGR + LS + F, renin-2 trans-
genic hypertensive rats fed low sodium diet
and given furosemide. ∗P < 0.05 compared
with basal values.
of bradykinin through the release of the vasodilators
prostacyclin, nitric oxide, or endothelium-derived hyper-
polarizing factor, and this effect is mediated by an Ang-
(1–7) receptor ([36–39], and for review see [11, 40]). In
addition, recent in vivo studies showed that Ang-(1–7)
exerts its functional effects also by binding to the G-
protein-coupled receptor Mas. Specific 125I-Ang-(1–7)
binding to Mas-transfected Chinese hamster ovary cells
showed a high affinity, and in vitro studies Ang-(1–7)
caused a concentration-dependent release of arachidonic
acid from these cells and an endothelium-dependent re-
laxation of mice aortic rings [41]. Therefore, it is most
likely that the vasodilator actions of Ang-(1–7) itself and
its interactions with other vasodilator systems are respon-
sible for Ang-(1–7)-dependent renoprotective actions in
salt-depleted normotensive HanSD rats and hyperten-
sive TGR, and in 2K1C Goldblatt hypertensive rats.
The finding that Ang-(1–7) does not play an impor-
tant role in the regulation of renal function in normoten-
sive HanSD rats and hypertensive TGR fed a NS diet
is in agreement with previous studies evaluating the
role of Ang-(1–7) in BP regulation of normotensive and
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Fig. 2. Percent changes in absolute (A) and
fractional (B) sodium excretion in response
to intrarenal Ang-(1–7) receptor blockade.
HanSD + NS, transgene-negative normoten-
sive rats fed normal sodium diet; Ang II, an-
giotensin II-infused hypertensive rats; 2K1C,
2-kidney, 1-clip Goldblatt hypertensive rats;
TGR + NS, renin-2 transgenic hypertensive
rats fed normal sodium diet; HanSD + LS + F,
transgene-negative normotensive rats fed low
sodium diet and given furosemide; TGR + LS
+ F, renin-2 transgenic hypertensive rats fed
low sodium diet and given furosemide. ∗P <
0.05 compared with basal values.
hypertensive rats. In support of this notion, it has been
shown that chronic blockade of Ang-(1–7) in salt-replete
normotensive rats, in TGR, or in spontaneously hyper-
tensive rats (SHR) did not cause significant increases in
BP [16, 17]. In addition, it has been shown that—in con-
trast to SHR—in TGR on a NS diet, the antihypertensive
effect of ACE inhibition was not associated with an in-
crease in urinary excretion of Ang-(1–7) [42]. Moreover,
we have recently demonstrated that plasma and kidney
Ang II levels in anesthetized salt-replete TGR during
their early phase of hypertension (50–52 days old) were
significantly lower than in age-matched salt-replete anes-
thetized HanSD rats [26]. It seems, therefore, reasonable
to assume that Ang-(1–7) concentrations in salt-replete
anesthetized TGR are not increased when compared with
HanSD rats, which may be the reason for the lack of renal
functional responses to Ang-(1–7) receptor blockade in
this model of hypertension.
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In this context, however, we should mention that in
our previous study [14], selective i.r. Ang-(1–7) recep-
tor blockade resulted in significant decreases in renal
hemodynamics and sodium excretion in normotensive
rats on normal sodium intake. We cannot provide a sat-
isfactory explanation for these apparently contradictory
findings because both studies were performed under the
same experimental conditions with regard to anesthesia,
diet, age of rats, compound, and dose of the Ang-(1–7)
receptor antagonist. However, a different strain of nor-
motensive rats, namely, male Wistar rats, was used in our
previous study [14], whereas in our present study we em-
ployed HanSD rats, a transgene-negative rat originating
from Sprague- Dawley rats. Since it has been reported
that differences in the genetic background among rat
colonies can alter the phenotype (for review see [43]),
it seems pertinent to assume that this factor might be re-
sponsible for the different results in our 2 studies. How-
ever, we cannot exclude that the overall state of sodium
balance, as well as small differences in the activity of the
RAS as a result of experimental manipulations, may have
influenced the renal actions of Ang-(1–7) as claimed by
Santos et al [12] in their comprehensive review.
The present findings suggest that Ang-(1–7) acts as an
important intrarenal vasodilator and natriuretic factor in
salt-depleted normotensive HanSD rats and hyperten-
sive TGR, as well as in 2K1C hypertensive rats. This
finding is in good agreement with previous studies in-
vestigating the role of Ang-(1–7) in BP regulation. They
showed that treatment with either a specific Ang-(1–7)
monoclonal antibody or the selective Ang-(1–7) recep-
tor antagonist elicited a dose-dependent rise in BP in
salt-restricted TGR and SHR, in whom salt restriction
caused marked increases in plasma Ang-(1–7) levels [16,
17]. In addition, an enhanced BP-lowering response to
the vasodilator action of Ang-(1–7) was found in the
2K1C hypertensive dog [9]. Moreover, it has been found
that chronic infusion of Ang-(1–7) significantly reduced
BP in salt-induced hypertension [44]. Furthermore, it has
been reported that the administration of the vasopepti-
dase inhibitor omapatrilat caused a BP decrease in salt-
sensitive hypertensive subjects that was accompanied
by a sustained increase in urinary Ang-(1–7) excretion
[45].
It is of particular interest that i.r. blockade of Ang-(1–
7) did not change renal function in Ang II-infused hyper-
tensive rats. This observation indicates that, in contrast to
2K1C Goldblatt hypertensive rats, which is one of the two
most extensively studied models of Ang II-dependent hy-
pertension, Ang-(1–7) does not exert a renoprotective
function in Ang II-infused hypertensive rats. Since Ang
II-infused and 2K1C Goldblatt hypertensive rats have
many common characteristic features (e.g., inappropri-
ately enhanced kidney Ang II levels) ([28–30, 46], and
for review see [2]), this difference in the intrarenal action
of Ang-(1–7) between these 2 Ang II-dependent models
is surprising. Moreover, the present finding in Ang II-
infused rats is, to some extent, contradictory to the results
of our previous study [14], which showed that acute i.r.
infusion of Ang-(1–7) did not attenuate the renal hemo-
dynamic responses to acute i.r. Ang II infusion but pre-
vented the decrease in sodium excretion induced by Ang
II. These divergent results may be reconciled by the fact
that in our previous study, Ang II and Ang-(1–7) were
acutely infused i.r. in normotensive rats [14], whereas in
the present study, hypertension was induced by chronic
administration of subpressor doses of Ang II, and renal
functional responses to Ang-(1–7) were evaluated in rats
in whom hypertensive vascular changes might have al-
ready occurred. Thus, it is possible that these differences
in the experimental protocols, in addition to the use of dif-
ferent rat strains, are responsible for the divergent results.
An alternative explanation for the different responses
to Ang-(1–7) receptor blockade in Ang II-infused and
2K1C Goldblatt hypertensive rats may be offered on
the basis of the recent discovery of the angiotensin-
converting enzyme 2 (ACE2), now considered as the
main enzyme responsible for the generation of Ang-(1–7)
([47] and for review see [48]). Thus, our current knowl-
edge of the RAS suggests, on one hand, a vasoconstrictor
axis with Ang II as the peptide with greatest biological
significance and, on the other hand, a vasodilator axis
with Ang-(1–7) as the dominant peptide of this pathway
(for review see [1, 2, 48, 49]). Since the catalytic efficiency
of ACE2 is approximately 400-fold higher for Ang II as
substrate than for Ang I [47], it may be assumed that
a compensatory up-regulation of ACE2, as observed in
response to other pathophysiologic stimuli [50, 51], may
not occur in Ang II-infused but is present in 2K1C rats.
Finally, with regard to the discrepant effects of Ang-(1–
7) receptor blockade on renal function in Ang II-infused
and 2K1C Goldblatt hypertensive rats, it should be em-
phasized that our experiments were performed in anes-
thetized surgically stressed animals. Even if renal renin
activity were markedly suppressed in Ang II-infused as
well as in 2K1C Goldblatt hypertensive rats [24–26], we
cannot exclude that they respond to anesthesia and sur-
gical procedures with different intrarenal RAS activity.
As previously noted [12], this may modify the renal func-
tional responses to Ang-(1–7) receptor blockade. Further
studies addressing this issue of different intrarenal actions
of Ang-(1–7) in Ang II-infused and 2K1C Goldblatt hy-
pertensive rats are needed.
Of special interest is also our observation that in TGR
subjected to salt depletion by administration of a diuretic
and subsequent salt restriction MAP was 22 mm Hg lower
than BP in TGR fed the NS diet. This finding indicates
that heterozygous TGR carry a salt-sensitive component
of hypertension, which is in accordance with recent ob-
servations made in our laboratory and by others [52–54].
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CONCLUSION
The present findings indicate that under conditions of
a normal salt intake and an enhanced activity of Ang II
due to administration of Ang II or by insertion of a renin
gene, Ang-(1–7) does not act as a counterbalancing reno-
protective agent. In contrast, under conditions of endoge-
nous RAS activation due to clipping of the renal artery
or to sodium depletion, Ang-(1–7) serves as an important
vasodilator and natriuretic paracrine factor in the regula-
tion of renal function. Whether, on one hand, the relative
lack of intrarenal Ang-(1–7) as a compensatory vasodila-
tory and natriuretic factor in TGR and Ang II-infused hy-
pertensive rats might partially contribute to the impaired
renal pressure-natriuresis mechanism and, thereby, to the
development and maintenance of hypertension in these
models, or whether, on the other hand, an enhanced in-
trarenal action of Ang-(1–7) might contribute to sustain
renal hemodynamics in salt-restricted rats and to atten-
uate hypertension in 2K1C Goldblatt hypertensive rats,
requires additional studies.
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